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BACKGROUND: Among patients using GnRH analogues for endometriosis it has been postulated that peripheral
and in¯ammation-induced in-situ aromatization of adrenal androgens are probably the main reasons for the high
rates of failure during follow-up. We hypothesized that in cases with premenopausal severe endometriosis, use of a
combination of anastrozole and goserelin to achieve almost maximal endocrine blockade of estrogen synthesis after
conservative surgery may increase the pain-free interval and reduce the recurrence rates as compared to goserelin
alone. METHODS: In a prospective randomized trial, we evaluated the ef®cacy of using either a combination of
anastrozole and goserelin for 6 months or goserelin alone for 6 months after conservative surgery for severe endo-
metriosis. The primary outcome measures were the symptom recurrence rates and the impact of treatment on
endometriosis-related multidimensional score. The secondary outcome measures were the impact of allocated treat-
ment regimens on menopausal quality of life and on lumbar spine bone mineral density (BMD). RESULTS: When
we analyzed the Kaplan±Meier survival curves, we detected a statistically signi®cant advantage of goserelin plus
anastrozole as compared to goserelin only, in terms of the median time to detect symptom recurrence (>2.4 versus
1.7 months; log-rank test; P = 0.0089). This statistically signi®cant advantage occurred with a relative risk of 4.3
[95% con®dence interval (CI) 1.3±9.8]. Three cases out of 40 recurred in the goserelin plus anastrozole arm (7.5%),
whereas we detected recurrences in 14 cases out of 40 cases in the goserelin-only arm (35%) during the follow-up
period of 24 months. Based on these data, the interpretation of Kaplan±Meier curves indicates that at the end of
follow-up, 54.7 versus 10.4%, respectively, of the patients were free of recurrence. The mean of the differences in
terms of Dbaseline±24 months post-medical therapy multidimensional score were statistically signi®cant in favour
of goserelin and anastrozole (9.2 6 2.1 versus 6.7 6 2.8; paired t-test; P < 0.0001; 95% CI 1.5±4.0). We observed a
statistically signi®cant difference in suppression of estradiol concentrations and a signi®cantly greater BMD loss at
the end of treatment in the goserelin and anastrozole arm as compared to goserelin-only arm. However, this did
not elicit deterioration in menopausal quality of life and the observed bone loss was not signi®cant in terms of
DBMD between the groups at 2 years of treatment withdrawal. CONCLUSIONS: Six months of treatment with
anastrozole and goserelin as compared to goserelin alone increased the pain-free interval and decreased symptom
recurrence rates in patients following surgery for severe endometriosis. Furthermore, menopausal quality of life
and BMD at 2 years after medical therapy remained unaffected
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Introduction
Even though yet to be determined, it is recommended that post-
operative adjuvant treatment should be instituted in order to
minimize the risk of recurrence and to extend the pain-free
period after conservative surgery in cases of severe endome-
triosis (American College of Obstetrics and Gynecology, 1999;
Gambone et al., 2002). For this purpose, treatment with GnRH
analogues for 6 months as post-surgical medical treatment has
been the preference of the last decade (Vercellini et al., 1998).
The desired treatment of the current decade is more targeted to
endometriotic foci either by surgery and/or by locally acting
medications in conjunction with ovarian blockade (Jones and
Sutton, 2001; Vignali et al., 2002).
Recently, the molecular basis for the local treatment of
endometriosis using an aromatase inhibitor has been discussed
(Bulun et al., 1998, 1999, 2001, 2001; Takayama et al., 1998;
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Zeitoun et al., 1999). According to these authors, the existence
of two additional extraovarian sources of endogenous estrogen
is probably an important reason for the high rate of failures
during follow-up among patients using GnRH analogues. The
®rst source is the peripheral aromatization of adrenal andro-
gens and the second is the in¯ammation-induced aromatization
in the endometriotic foci itself. GnRH analogues are ineffect-
ive in both of these estrogen production sites. Aromatase
inhibitors are not able to inhibit ovarian function in
premenopausal women and thus they are not able to create
the desired almost complete hypoestrogenic milieu. The
authors postulated that the addition of aromatase inhibitors to
GnRH analogues in premenopausal patients could increase the
disease-free interval by inhibiting both the ovarian and above-
mentioned two important extraovarian sources of estradiol
(E2).
Given this background, to test the clinical signi®cance of this
new hypothesis related to the two-drug adjuvant regimen, we
conducted a prospective randomized study. We tried to answer
the question whether anastrozole (Arimidex 1 mg; Astra-
Zeneca, Maccles®eld, UK), a third-generation aromatase
inhibitor, in conjunction with the GnRH analogue goserelin
(Zoladex 3.6 mg; Astra-Zeneca) could lower the recurrence
rates and thus extend the symptom-free interval with accept-
able morbidity as compared to goserelin alone after conserva-
tive surgery in severe endometriosis cases.
Materials and methods
Participants
This post-surgical medical therapy trial was undertaken between
December 1998 and March 2003 among patients with severe baseline
endometriosis (rASRM score >40) according to the American Society
for Reproductive Medicine (American Society for Reproductive
Medicine, 1997). All patients were surgically treated by a conservative
approach between December 1998 and September 2000. This trial was
conducted after the approval of the ethics committee of the institution
and all subjects gave written informed consent to the trial protocol.
Interventions
In patients with a clinical suspicion of severe endometriosis, baseline
grading of symptoms and physical ®ndings was performed before the
surgery according to the previously developed and widely used
multidimensional scale (Biberoglu and Behrman, 1981). In this scale,
symptoms of dysmenorrhoea, dysparenuia and pelvic pain were each
scored by the patient, and the physical ®ndings of pelvic tenderness
and indurations were each scored by the physician as: none (0 point),
minimal (1 point), moderate (2 points) or severe (3 points). The sum of
these variables compromised the Total Pelvic Symptom Score (TPSS).
In this trial, TPSS is considered to be the subjective clinical indicator
of the disease severity at baseline and during the follow-up period of
the study. After grading the TPSS as the sum of the symptoms and
physical ®ndings, all patients were subjected to diagnostic laparo-
scopy. Laparoscopy with histological proof was the ultimate tool to
diagnose endometriosis at baseline. Laparoscopy is also considered to
be the objective clinical indicator of disease severity and it was
programmed in the luteal phase of the cycle. Among patients who had
rASRM scores >40, the diagnosis of severe endometriosis was made
and we attempted a thorough conservative surgery either by
laparoscopy or laparotomy.
After the thorough conservative surgery, patients were considered
eligible for the post-surgical medical therapy trial. Exclusion criteria
included further desire for childbearing, any treatment for endome-
triosis within the previous 3 months, any concomitant disease that can
be an established cause of chronic pelvic pain (in¯ammation sequela,
myoma, pelvic congestion, adenomyosis, etc.), osteopenia or osteo-
porosis at bone mineral density (BMD) measurements according to the
World Health Organization (1994) and any concomitant disease that
can be a contraindication to goserelin or anastrozole.
In all patients, we prescribed 600 mg elemental Ca and 400 IU
vitamin D (b.i.d.) in a commercially available medication (Cal D Vita;
Roche, Basel, Switzerland). The ®rst group of patients received
anastrozole 1 mg/day plus s.c. depot injections of 3.6 mg goserelin
every 4 weeks for 24 weeks with the ®rst injection given in the ®rst
late luteal week of the menstrual cycle before discharge. The second
group of patients received a placebo tablet in addition to the above-
mentioned goserelin regimen for 24 weeks. Patients were evaluated at
24 weeks of medical treatment, and at 6, 12, 18 and 24 months after
the end of medical treatment.
Objectives and outcomes
The main objective of this trial was to assess the clinical ef®cacy of
anastrozole in conjunction with goserelin as compared to goserelin
alone in the adjuvant setting. Thus the primary outcome measures of
this trial were (i) the recurrence rate and (ii) the impact of allocated
treatments on TPSS during the follow-up period of 24 months after the
end of medical treatment.
During this trial, recurrence was de®ned as symptoms and physical
®ndings suggesting endometriosis with a TPSS of >7 that requires
alternative treatment at any time during the follow-up period of 24
months after the end of post-surgical medical treatment. Laparoscopy
to diagnose recurrent endometriosis was not considered to be
necessary in accordance with the recent literature (Hornstein et al.,
1997; American College of Obstetrics and Gynecology, 1999; Ling,
1999; Vercellini et al., 1999; Winkel, 2000; Gambone et al., 2002).
Thorough history taking, complete physical and detailed pelvic
examination, transvaginal sonography, urinalysis, complete blood
count, and endocervical examination to rule out chlamydia and
gonococcus were performed to rule out pain syndromes other than
endometriosis. The time to initiate alternative treatment was recorded
for each patient. Examinations to detect recurrences were scheduled
either by the request of the patient (whenever the patients had
complaints, they were immediately examined to detect recurrences) or
at the time of scheduled follow-up examinations at the immediate end
of post-surgical medical treatment (24 weeks exam), and at 6, 12, 18
and 24 months post-surgical medical treatment. Symptoms of TPSS
recorded by the patients (dysmenorrhoea, dysparenuia, pelvic pain)
were studied as TPSS-Patient (TPSS-P). In each exam, TPSS was re-
evaluated by the surgeons and noted for statistical analysis, and the
probability of recurrence noted. During the study period we were able
to record TPSS at baseline, at 24 weeks post-surgical medical
treatment, and at 6, 12, 18 and 24 months post-surgical medical
treatment. Whenever a recurrence was detected (TPSS >7), we
offered GnRH analogue plus add-back or de®nitive surgery as second-
line treatments.
The secondary outcome measures of this trial were established to
evaluate the adverse effects of therapy and were studied in two
aspects. The ®rst secondary outcome measure is the impact of
treatment on the menopausal quality of life according to the 24-week
examination ®ndings and E2 levels throughout the therapy. In order to
assess the severity of climacteric symptoms as a measure of quality of
life induced by the drug regimens, the modi®ed Greene scale and
Blatt±Kupperman Index were used (Greene, 1998; Alder, 1998). The
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validity and sensitivity of these scales have been established in
climacteric research. These classi®cation systems, though simple,
construct a comprehensive measure of the multi-faceted and wide
ranging symptom picture presented by the climacteric women. The
modi®ed Greene scale was used to determine the severity of
vasomotor, somatic, psychological symptoms (anxiety and depres-
sion) and loss of sexual interest (Greene, 1998). The Blatt±Kupperman
Index, in contrast, does not assess sexual interest, but vasomotor
symptoms are of prime importance in this scale (Alder, 1998). All
patients were instructed to self record the scales at 24 weeks of
evaluation during the post-surgical medical treatment. The scales were
reviewed and scored by a blinded psychiatrist. In order to assess the
impact of treatment regimens on E2 concentrations, blood samples
were taken before the second, fourth and sixth goserelin administra-
tions, and free E2 levels were measured.
The second secondary outcome measure is the impact of medical
treatment on L1±L4 vertebra BMD at 24 weeks of medical therapy and
24 months post-surgical medical treatment. Variables were studied at
baseline, at 24 weeks of post-surgical medical treatment and at the end
of the study period, i.e. 24 months after the post-surgical medical
treatment. The BMD of the lumbar vertebra (L1±L4) were measured
by dual-energy X-ray absorptiometry with the use of Hologic QRD
(Hologic, Waltham, MA). The coef®cient of variation of the machine
over the study period was 3.5%.
Sample size calculation
In calculating the sample size required, the primary assessment was
the recurrence rates. A 31% recurrence rate after laparoscopic
reductive surgery and post-surgical treatment with a GnRH analogue
has been reported (Hornstein et al., 1997). We expected a decrease in
recurrence rates after laparoscopic conservative surgery and post-
surgical treatment with anastrozole plus goserelin. A difference of
25% between the allocated treatments was considered signi®cant. To
have a 90% chance of detecting such a difference at an overall
signi®cance level of 5%, 40 patients for each group were required.
Randomization process and masking
Treatment allocation was performed in accordance with a computer-
generated randomization sequence using numbered, opaque, sealed
envelopes. The research assistants prescribed the drugs. Neither the
surgeons nor the patients were aware of the regimen prescribed during
the evaluation of TPSS recurrence during the study period.
Randomization code was broken and unblinding occurred at the
time of the diagnosis of recurrence.
Statistical methods
StatMate and Prism Software for Windows (Graph Pad) were used in
the randomization process, sample size calculation and statistical
analysis of this trial.
All raw data were tested to con®rm the Gaussian distribution using
the Kolmogorov±Smirnov test. The cumulative proportion of recur-
rences by plotting percent recurrences as a function of time was
estimated by the method of Kaplan and Meier. The survival curves for
each allocated treatment were compared with the log-rank test. The
impact of treatment on TPSS as a primary outcome measure is studied
in the ef®cacy-evaluable population; in order to mitigate the bias that
would result from the missing data, we carried out the `last
observation carried forward procedure'. In this procedure, a patient's
last measured response is applied to the subsequent scheduled
observations for which data are not available and included in the
statistical analysis (Archer and Pickar, 2002). Thus, for example, the
TPSS of a patient with recurrence at 17 months is studied in the 18
months scheduled examination. In order to quantify the impact of
treatment arms on TPSS during the study period, the non-parametric
repeated measures ANOVA (Friedman test) with Dunn as the post-test
was used. The differences of treatment effects on TPSS were assessed
by the paired t-test and Wilcoxon matched-pairs signed-rank test. In
the statistical analysis of the secondary outcome variables, intention-
to-treat analysis (Archer and Pickar, 2002) was used; thus, it included
the dropouts for whom data are not available at 24 months after post-
surgical medical treatment. P < 0.05 was considered statistically
signi®cant.
Results
Participant ¯ow, recruitment and baseline data
Ninety-seven women treated with conservative surgery
between December 1998 and September 2000 for baseline
severe endometriosis were considered eligible for the post-
surgical medical treatment trial. Seventeen of them were
excludedÐeight patients refused randomization (®ve of them
were treated by goserelin and anastrozole, three of them were
by goserelin), in six patients osteopenia or osteoporosis was
detected (they were treated by goserelin and weekly alendro-
nate) and three patients chose not to receive treatment, but
instead just to be monitored. The remaining 80 subjects were
randomized and were followed for at least 24 months after the
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post-surgical medical treatment of 6 months. None of the
randomized subjects were lost during the study period and for
no patient violations of the study protocol occurred. The
diagrammatic ¯ow of the participants is given in Figure 1. The
baseline demographic and clinical characteristics of each group
are given in Table I. The baseline variables were statistically
similar in each group.
Analysis: outcome and estimation
The survival curves obtained for the treatment arms are plotted
in Figure 2. When we analyzed the Kaplan±Meier survival
curves, we detected a statistically signi®cant advantage in
favour of goserelin plus anastrozole as compared to goserelin
only, in terms of the median time to detect symptom recurrence
(>24 versus 17 months; log-rank test; P = 0.0089). This
statistically signi®cant advantage occurred with a relative risk
(RR) of 4.3 [95% con®dence interval (CI) 1.3±9.8]. Three
cases out of 40 recurred in the goserelin plus anastrozole arm
(7.5%), whereas we detected recurrences in 14 cases out of 40
cases in the goserelin-only arm (35%) during the follow-up
period of 24 months. Based on these data, the interpretation of
Kaplan±Meier curves indicates that at the end of follow-up,
54.7 versus 10.4%, respectively, of the patients were free of
recurrence.
In this trial, both treatment protocols proved to be statistic-
ally effective in reducing the TPSS during the study period
(Figure 3). The comparisons of the impact of allocated
treatments in terms of TPSS and `TPSS-P' between the two
Figure 2. Kaplan±Meier curves for patients treated with goserelin versus goserelin plus anastrozole.
Figure 3. The impact of treatment arms on TPSS, plasma E2, climacteric quality of life and BMD. *Post-medical therapy.
Table I. Baseline demographic and clinical characteristics of each group
(mean 6 SD)
Goserelin plus anastrozole Goserelin
Age 31.3 (65.7) 32.4 (66.1)
Body mass index 23.6 (61.47) 24.5 (61.31)
Gravidity 2.50 (60.9) 2.57 (60.9)
rASRM scores 61.2 (614.2) 63.2 (613.3)
Baseline TPSSa 12.7 (61.2) 12.8 (61.3)
Baseline TPSS-Pb 7.8 (60.9) 7.9 (60.8)
L1±L4 BMD (g/cm2) 1085 (634.3) 1088 (626.4)
aTotal pelvic symptom score.
bThe sum of dysmenorrhoea, dysparenuia and pelvic pain.










niversity user on 18 January 2021
regimens are given in Table II The mean of the differences
between the groups in terms of TPSS either at baseline or at 24
weeks of evaluation are not statistically signi®cant. The mean/
median of the differences between treatment regimens at 6, 12,
18 and 24 months post-treatment evaluation is statistically
signi®cant in favour of goserelin and anastrozole. The effect of
allocated treatments in terms of DTPSS and of DTPSS-P is
given in Table III. We were unable to detect a signi®cant
difference in terms of DTPSS (baseline±24 weeks evaluation)
and DTPSS-P (baseline±24 weeks evaluation) between the
allocated treatment arms. However, we detected a statistically
signi®cant difference in terms of DTPSS and DTPSS-P at 24
months post-treatment evaluation in favour of goserelin and
anastrozole.
We also tested the impact of treatment regimens on speci®c
symptoms as components of TPSS (Table IV). We detected a
statistically signi®cant difference in favour of goserelin plus
anastrozole in terms of each symptom score and in terms of
DBaseline±24 months post-medical therapy (PMT) scores of
each symptom.
Furthermore, we tested the treatment arms in terms of their
capacity to maintain their ef®cacy over the time frame of the
Table II. The impact of post-surgical medical treatment on TPSS and TPSS-P (mean 6 SD)
Goserelin plus anastrozole Goserelin P value (95% CI)
TPSS
TPSS baseline 12.7 (61.2) 12.8 (61.3) 0.72a (±0.4 to 0.6)
TPSS at 24 weeks 3.1 (60.8) 3.3 (60.9) 0.40a (±3.4 to 1.4)
TPSS 6 months PMT 3.5 (60.9) 4.4 (61.5) <0.001b (0.3±1.5)
TPSS 12 months PMT 3.5 (61.4) 5.8 (62.1) <0.0001a (1.3±3.2)
TPSS 18 months PMT 3.6 (61.7) 6.4 (62.2) <0.0001a (1.8±3.7)
TPSS 24 months PMT 3.5 (61.7) 6.4 (62.6) <0.0001a (1.8±3.9)
TPSS-P
TPSS-P baseline 7.8 (60.9) 7.9 (60.8) 0.61a (±0.2 to 0.4)
TPSS-P at 24 weeks 2.2 (60.7) 2.2 (60.6) 0.89b (±0.3 to 0.2)
TPSS-P 24 months PMT 2.8 (60.7) 4.6 (60.8) <0.0001b (1.4±2.2)
aPaired t-test.
bWilcoxon matched-pairs signed-rank test.
Table III. The impact of post-surgical medical treatment on DTPSS and on DTPSS-P (mean 6 SD)
Goserelin plus anastrozole Goserelin P value (95% CI)
DTPSS
DTPSS baseline±24 weeks 9.6 (61.5) 9.5 (61.8) 0.88a (±0.7 to 0.6)
DTPSS baseline±24 months PMT 9.2 (62.1) 6.7 (62.8) <0.0001a (1.5±4.0)
DTPSS-P
DTPSS-P baseline±24 weeks 5.6 (61.1) 5.7 (61.1) 0.9b (±0.4 to 0.6)
DTPSS-P baseline±24 months PMT 5.0 ((61.3) 3.3 (61.2) <0.0001a (1.1±2.3)
aPaired t-test.
bWilcoxon matched-pairs signed-rank test.
Table IV. The impact of treatment regimens on speci®c symptoms' verbal rating scores (dysmenorrhoea, dysparenuia and pelvic pain) at 24 week of medical
therapy (MT) and at 24 months PMT (mean 6 SD)
Goserelin plus anastrozole Goserelin P value (95% CI)a
Dysmenorrhoea
Baseline 2.7 (60.5) 2.6 (60.6) 0.42 (±0.3 to 0.1)
24 weeks of MT 0.9 (60.5) 1.1 (60.5) 0.33 (±0.1 to 0.4)
24 months PMT 1.4 (60.5) 1.7 (60.7) <0.05 (0.03 to 0.6)
DBaseline±24 weeks 1.7 (60.8) 1.5 (60.8) 0.29 (±0.6 to 0.1)
DBaseline±24 months 1.3 (60.7) 0.8 (60.9) <0.05 (±0.8 to ±0.04)
Dysparenuia
Baseline 2.6 (60.6) 2.6 (60.5) 0.71 (±0.2 to 0.3)
24 weeks of MT 0.52 (60.5) 0.50 (60.5) 0.82 (±0.2 to 0.2)
24 months PMT 0.6 (60.5) 1.4 (60.8) <0.0001 (0.4 to 1.0)
DBaseline±24 weeks 2.1 (60.7) 2.1 (60.8) 0.54 (±0.3 to 0.4)
DBaseline±24 months 1.9 (60.8) 1.2 (61.0) <0.001 (±1.0 to ±0.2)
Pelvic Pain
Baseline 2.6 (60.7) 2.7 (60.5) 0.41 (±0.1 to 0.3)
24 weeks of MT 0.7 (60.6) 0.6 (60.5) 0.24 (±0.3 to 0.07)
24 months PMT 0.7 (60.5) 1.5 (60.5) <0.0001 (0.5 to 1.0)
DBaseline±24 weeks 1.8 (61.0) 2.0 (60.7) 0.13 (±0.07 to 0.5)
DBaseline±24 months 1.8 (60.9) 1.1 (60.6) <0.001 (±1.1 to ±0.3)
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study. The results of the non-parametric repeated measures
ANOVA (Friedman test with Dunn's multiple comparisons test
as the post-test) for each group indicates that in both groups
when compared to baseline TPSS, the variation among column
medians during the follow-up is signi®cantly greater than
expected by chance (P < 0.0001). In the goserelin and
anastrozole regimen from 24 weeks on, the variation among
column medians was not signi®cantly greater than expected by
chance (P = 0.675) during the remaining follow-up period,
indicating the maintenance of ef®cacy (Figure 3). However,
this was not the case in the goserelin armÐwe were able to
detect a statistically signi®cant variation among column
medians at 24 weeks versus 18 months post-treatment [rank
sum difference (RSD) ±82, P < 0.01], at 24 weeks versus 24
months post-treatment (RSD ±76; P < 0.001) and at 6 versus 12
months post-treatment (RDS ±31.5; P < 0.001) during the
follow-up period. This indicates a stepwise increase of TPSS in
the goserelin arm within the time frame of the study (Figure 3).
Adverse events
The impact of treatment regimens on E2 levels and on
climacteric symptoms as a measure of quality of life during
the treatment period is given in Figure 3. In the repeated
measures, one-way ANOVA test done separately for each
group, we do not have evidence that free E2 concentrations
differed through the therapy period (P = 0.69 for goserelin; P =
0.47 for goserelin plus anastrozole). However, goserelin plus
anastrozole lowered E2 concentrations signi®cantly as com-
pared to the goserelin-only regimen (Table V). In contrast, the
mean of the differences between the treatment regimens either
in terms of modi®ed Greene scale scores or the Blatt±
Kupperman index scores as a measure of menopausal quality
of life at 24 weeks of evaluation are not statistically signi®cant
(Table IV).
We noted that patients in the goserelin plus anastrozole arm
lost 7.7% of their baseline L1±L4 BMD at 24 weeks evaluation
and 2.3% of their baseline L1±L4 BMD at 24 months of
treatment withdrawal. The representative BMD losses in the
goserelin arm were 4.9 and 2.1%, respectively (Figure 3).
These losses were statistically signi®cant either at 24 weeks of
evaluation or at 24 months of treatment withdrawal (Table V).
Then, we compared the DBMD measurements between groups
in order to compare the allocated treatments. We found a
statistically signi®cantly greater bone loss in the goserelin plus
anastrozole arm at 24 weeks of evaluation (Table IV).
However, we noted no statistically signi®cant differences
between the allocated treatments in the mean of the Dbaseline±
24 months post-surgical medical treatment (Table V).
Discussion
Endometriosis, as it still recurs after currently recommended
therapy, requires, more than ever, fully integrated medical and
surgical management, and an ongoing dialogue with laboratory
scientists. Keeping this in mind, we would like to discuss (i) the
rationale of our adjunctive regimens we have chosen in this
trial, (ii) the impact of anastrozole in conjunction with
goserelin on recurrence rates and on chronic pelvic symptoms
and signs of endometriosis, and (iii) the side-effects of the
double-drug adjuvant regimen in comparison to goserelin.
In a signi®cant proportion of patients, the pain related to
endometriosis eventually returns. One explanation for the
observed long-term inef®ciency of GnRH analogues is the
presence of signi®cant E2 production that continues in the adi-
pose tissue, skin and endometriotic foci per se during the
GnRH analogue treatment. In¯ammation-induced aromatiza-
tion in the endometriotic foci itself represents the intra-acrine
mechanism of estrogen action in endometriosis. The prosta-
glandin E2 content, the aberrant expression of aromatase, the
presence of 17b HSD Type 1 and the absence of 17b HDS Type
2 collectively raise the local levels of E2 of the ectopic
endometrial tissues. Furthermore, GnRH analogues are inef-
fective to stop peripheral aromatization of androstenedione in
adipose tissue and skin ®broblasts; therefore, there is an
ongoing peripheral supply of estrone and E2 to the target foci
that are rich in 17b HSD Type 1 (Takayama et al., 1998; Bulun
et al., 1998, 1999, 2000, 2001; Zeitoun et al., 1999; Vignali
et al., 2002).
In this trial we did not include a placebo group because it
seemed unethical to us given the proven effectiveness of GnRH
analogues and current practice (Vercellini et al., 1998;
American College of Obstetrics and Gynecology, 1999;
Winkel, 1999; Jones and Sutton, 2001; Gambone et al.,
2002; Vignali et al., 2002). Therefore, we have chosen
goserelin as the standard arm of the trial. We intended to
increase the hypoestrogenism by the double-drug regimen both
centrally and peripherally. Aromatase inhibitors given alone
are not able to completely inhibit ovarian steroidogenesis
(Vignali et al., 2002), and, furthermore, may increase follicular
recruitment (Mitwally and Casper, 2001) and may lead to
ovarian stimulation and cyst formation. Given alone they are
only suf®ciently potent to block extraovarian estrogen pro-
Table V. The impact of allocated treatment on secondary outcome measures
Goserelin plus anastrozole Goserelin P valuea (95% CI)
Plasma E2 (pmol/l) 8 weeks 22.7 (63.6) 49.8 (64.3) <0.0001 (25±28)
Plasma E2 (pmol/l) 16 weeks 23.6 (63.1) 49.5 (63.7) <0.0001 (24±27)
Plasma E2 (pmol/l) 24 weeks 23.7 (63.5) 49.1 (63.7) <0.0001 (23±27)
Greene scale score 30.3 (61.9) 29.5 (61.9) 0.20 (±1.5 to 0.3)
Blatt±Kuppermann score 54.1 (64.7) 53.9 (66.0) 0.90 (±2.5 to 2.2)
D L1±L4 BMD 24 weeks 93.8 (633.2) 60.2 (628.2) 0.003 (±50.5 to ±16.7)
D L1±L4 BMD 24 months 27.1 (646.3) 25.2 (628.9) 0.46 (±16.9 to 36.4)
aPaired t-test.
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duction (Dowsett, 1999; Santen and Harvey, 1999; Vignali
et al., 2002). However, in the presence of a GnRH analogue
which itself results in ovarian inhibition, aromatase inhibitors
are effective to achieve near maximal estrogen suppression
(Dowsett, 1999; Santen and Harvey, 1999). Therefore, in this
trial we tested the ef®cacy of anastrozole in the presence of
ovarian inhibition and did not have an anastrozole-only group.
In the experimental arm of this trial, goserelin was used in
order to inhibit ovarian steroidogenesis, and anastrozole to
inhibit the consequences of peripheral aromatization and the
aberrant expression of aromatase in the endometriotic foci.
When we analyzed the Kaplan±Meier survival curves, we
detected a statistically signi®cant advantage in favour of
goserelin plus anastrozole as compared to goserelin only, in
terms of the median time to detect symptom recurrence (>24
versus 17 months; log-rank test; P = 0.0089). This statistically
signi®cant advantage occurred with an RR of 4.3 (95% CI 1.3±
9.8). Three cases out of 40 recurred (TPSS >7) in the goserelin
plus anastrozole arm (7.5%), whereas we detected recurrences
in 14 cases out of 40 cases in the goserelin-only arm (35%)
during the follow-up period of 24 months. Based on these data,
the interpretation of Kaplan±Meier curves indicates that at the
end of follow-up, 54.7 versus 10.4%, respectively, of patients
were free of recurrence. The median time to detect recurrence
in the goserelin treatment arm was 17 months post-treatment.
In contrast, the median time to detect recurrence in the
goserelin and anastrozole arm was >24 months.
In this trial both treatment protocols proved to be statistically
effective in reducing the TPSS; however, we observed a more
profound, stable and long-lasting effect of goserelin and
anastrozole on TPSS during the study period. Furthermore, the
impact of treatment in terms of TPSS and individual symptom
score reduction was statistically relevant in favour of goserelin
and anastrozole. Based on our data, we argue that almost
complete targeted endocrine blockade of estrogen biosynthesis
in the adjuvant setting after conservative surgery involving
goserelin and anastrozole is superior to the standard approach.
This novel approach was associated with a lower rate of
recurrence and better, continuous symptom control within the
time frame of the study.
The most common adverse effects of GnRH analogues are
associated with hypo-estrogenism. Our data clearly demon-
strates that anastrozole is a very effective suppressant of E2
concentration even in the presence of the GnRH analogue
goserelin. However, it was interesting to note that this
combination was tolerated as well as goserelin only in the
context of the climacteric quality of life. The mean of the
differences between the treatment regimens either in terms of
modi®ed Greene scale or the Blatt±Kupperman index scores as
measures of climacteric quality of life were not statistically
signi®cant. The explanation for this unexpected ®nding may be
our sample size, which is relatively small to study the
differences in quality of life or the inef®ciency of the arma-
mentarium available today to detect differences in the meno-
pausal quality of life below a threshold value of E2 or the
biological suppression we have detected is not of clinical
relevance. Even though not studied in our population, it may
also be related to the dynamics of sex hormone-binding
globulin and free testosterone in the presence of goserelin and
anastrozole, as it theoretically leads to an increase in free
testosterone indices.
To our knowledge the impact of double-drug regimen to
BMD of women with endometriosis has not been reported in
the literature. Both regimens had signi®cant detrimental impact
on BMD even after treatment withdrawal. The observed BMD
loss was statistically more pronounced at 24 weeks of
evaluation in the goserelin plus anastrozole arm. Even though
the bone loss did not recover at 24 months of evaluation, none
of our patients were osteopenic or osteoporotic according to
WHO criteria either at 24 weeks or at 24 months of post-
surgical medical treatment evaluation. In our opinion this
®nding is very important from the clinical standpoint, because
for women with no history of fragility fracture, only WHO
de®nitions of osteopenia and osteoporosis are associated with a
high risk of fracture (American Association of Clinical
Endocrinologists, 2001). Furthermore, the physiological bone
loss of 0.5% per year that is evident after the third decade
should also be taken into account (Stevenson et al., 1989). Our
statistical results point to a signi®cant loss of BMD in L2±L4 at
24 weeks and 24 months of evaluation within each treatment
arm; however, the size of the bone loss being signi®cant in
favour of goserelin at the end of treatment is not signi®cant at 2
years after treatment. The masking of bone loss with bispho-
sphonates may be considered; however, this has not been
studied in our patients.
In our local practice the costs of a 6-month treatment with
goserelin plus anastrozole and goserelin are around US$2500
and 1250, respectively. Even though measuring the cost-
effectiveness is beyond the scope of this trial, in the era of
managed care medicine the costs of our drugs must be
interpreted cautiously with regard to the limited costs and
ef®cacy of their alternatives, particularly progestins with or
without estrogens (Vercellini et al., 2003).
In conclusion, we showed that in patients with severe
endometriosis after conservative surgery, almost maximal
endocrine blockade of estrogen synthesis achieved with
anastrozole and goserelin for 6 months as a post-surgical
medical treatment is a rational treatment. On the basis of the
presented ®ndings, this combination in the adjuvant setting
increases the pain-free interval, decreases recurrence rates, and
improves symptom control without further deteriorating the
menopausal quality of life and bone metabolism. In our
opinion, key targets for future development in the treatment of
severe endometriosis are (i) further assessment of the potential
role of aromatase inhibition in premenopausal patients, (ii)
strategies to enhance the degree of hormone suppression for
prolonged periods without deteriorating the bone, (iii) inves-
tigation of the optimal sequential use of different compounds
such as estrogens/progestogens, immunomodulators and anti-
in¯ammatory agents in addition to GnRH analogues and
aromatase inhibitors.
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